How effective is stem cell therapy for kidney disease?

A 2025 systematic review and meta-analysis in Cells found that MSCs improved kidney function and reduced inflammatory markers in animal models of chronic kidney disease (CKD), and that both animal and human studies showed a significant reduction in the urine albumin-to-creatinine ratio. At Stem Cell Mexico, kidney protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, given by intravenous (IV) infusion after a review of your recent blood work, and effectiveness is measured with the same lab tests before and after treatment. Some patients also report better energy and well-being. Results vary with the stage and cause of kidney disease, and treatment works best as a complement to proven nephrology care.

This guide explains how effectiveness is measured in kidney disease, what research has found, which factors influence results and what a realistic follow-up plan looks like.

How effectiveness is measured in kidney disease

Kidney health is followed with a few key measures, which are also the best way to evaluate any treatment:

• eGFR (estimated glomerular filtration rate): an estimate of how well the kidneys filter, calculated from blood creatinine. It defines the stage of CKD.
• Creatinine and BUN: waste products in the blood that rise when filtration falls.
• Urine albumin-to-creatinine ratio (UACR): measures protein leaking into the urine. Higher values mean more kidney stress and a higher risk of progression; lowering UACR is a goal of standard kidney care.
• Electrolytes, hemoglobin and bone markers: reflect complications of CKD.
• Blood pressure and blood sugar: major drivers of kidney damage.
• Symptoms and quality of life: energy, appetite, swelling, sleep and daily function.

According to the KDIGO 2024 guideline, both eGFR and albuminuria are used to classify CKD and estimate risk, which is why both are followed after any treatment.

What the research has found

Kidney-protective effects

The 2025 meta-analysis in Cells analyzed 52 studies of MSCs in CKD. In animal models, MSCs significantly lowered creatinine, improved filtration and reduced inflammatory markers. These results support the idea that MSC signals can protect kidney tissue.

Protein in the urine

The same review included three randomized controlled trials in humans with 86 participants. Across animal and human studies, MSC therapy significantly reduced the urine albumin-to-creatinine ratio. Because protein leakage is closely associated with progression, this is one of the most relevant findings for patients.

Mechanisms

MSCs from Wharton's jelly release anti-inflammatory and protective factors that may reduce chronic inflammation, support the small blood vessels of the kidney, protect remaining kidney cells and limit fibrosis. These mechanisms are consistent with the reduction in protein leakage and inflammatory markers observed in studies.

Safety

A 2026 meta-analysis of IV umbilical-cord-derived MSCs in Stem Cells Translational Medicine found temporary fever to be the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled trials.

What "effective" can look like for you

Realistic, measurable signs of benefit include:

• A lower UACR on follow-up tests.
• A stable eGFR over time, especially in people whose eGFR had been declining.
• Better energy, appetite and daily function, which some patients report.
• Fewer inflammatory flares in some inflammatory kidney conditions.
• Good tolerance of the infusion, with no change needed in your usual kidney medications.

Kidney disease changes slowly, so comparing results at three and six months with your baseline gives a clearer picture than a single test. Day-to-day values can vary with hydration, recent exercise, diet and infections, which is why trends over several tests are more meaningful than any one result, and why tests are best repeated under similar conditions.

Factors that influence results

• Stage of CKD: earlier stages have more remaining nephrons to protect, so stabilization is more achievable. In advanced stages and in dialysis, goals focus on well-being and safety.
• Cause of kidney disease: inflammatory and diabetic kidney disease may respond differently from inherited conditions such as polycystic kidney disease.
• Amount of protein in the urine: higher protein leakage leaves more room for measurable improvement.
• Blood pressure and blood sugar control: uncontrolled values continue to damage the kidneys and can offset any benefit.
• Medications: kidney-protective medications such as ACE inhibitors, angiotensin receptor blockers and SGLT2 inhibitors should continue; anti-inflammatory painkillers should be avoided.
• Lifestyle: salt intake, weight, smoking, sleep and physical activity all affect kidney health.

A typical timeline

• First days: some patients feel tired or have a mild temporary fever after the infusion.
• Weeks to months: some patients report better energy or well-being.
• One, three and six months: repeat kidney labs, compared with your baseline.
• Beyond six months: your nephrologist continues to monitor your kidney function as part of routine care.

What our patients usually receive

Based on the treatment plans our team prepares for kidney patients, a typical protocol at Stem Cell Mexico includes:

• A review of your recent blood work before confirming the plan, commonly including creatinine, BUN, albumin, liver enzymes, glucose and HbA1c, iron, lipid panel, uric acid, urinalysis, vitamin D, electrolytes and a renal ultrasound.
• Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on body weight and medical review, with careful control of fluid volume.
• One night at our facilities with nursing and medical monitoring.
• Consultation with your doctor and the stem cell specialist and ground transportation from the San Diego airport area.

Kidney plans are quoted individually. Our team stays in contact after treatment to follow your progress and decide, together with your lab results, whether a second application could help.

How treatment fits with standard care

The KDIGO 2024 guideline and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) emphasize blood pressure and blood sugar control, kidney-protective medications, diet adjustments, avoiding kidney-toxic drugs and regular monitoring. These measures remain the foundation of kidney care. Regenerative treatment is added to them, and no medication should be stopped because of it.

Common questions from kidney patients

Will I need more than one application? Some patients receive a single infusion, and others a second one months later. The decision is based on your follow-up labs, how you feel and the doctor's review, rather than on a fixed schedule.

Do I need to stop any medications? No kidney or blood pressure medication should be stopped because of the treatment. The doctor will review anti-inflammatory painkillers and supplements, which are usually paused around the infusion.

Can I travel if I am on dialysis? Yes, in most cases, with planning. The visit is organized around your dialysis schedule, and the infusion volume is kept low. Expectations focus on well-being rather than on recovering kidney function.

Will my nephrologist be involved? We encourage it. Sharing your baseline and follow-up labs with your nephrologist keeps your care coordinated and makes it easier to see any change.

How soon will I see changes in my labs? Kidney values change slowly. Labs at three and six months are more informative than a test a few days after treatment.

Who may be a candidate

• CKD with stable kidney function and recent lab results.
• Controlled blood pressure, safe potassium levels and manageable fluid status.
• Continued follow-up with a nephrologist.
• No active infection and no cancer within the past five years.

Dialysis patients and kidney transplant recipients are evaluated individually, with goals adapted to their situation and coordination with their dialysis or transplant team.

Warning signs when comparing clinics

Be cautious if a clinic:

• Reports success percentages, such as "regenerated kidneys", without published data.
• Promises to help you stop dialysis.
• Suggests stopping kidney medications.
• Does not request recent blood work.
• Says the treatment is risk-free.

Questions to ask during your evaluation

• Which lab results will we use to measure effectiveness?
• What results are realistic for my stage and cause of kidney disease?
• How many cells are recommended, and why?
• When should I repeat my labs?
• How will you share results with my nephrologist?

Bottom line

Stem cell therapy for kidney disease is effective as a supportive treatment: research shows reduced protein in the urine and reduced inflammation, with a reassuring safety profile, and some patients report better energy and well-being. At Stem Cell Mexico, Wharton's jelly MSCs are given by IV infusion after a review of your blood work, as a complement to nephrology care, and results, which vary between individuals, are measured with the same labs before and after treatment. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your kidney condition, goals and medical history.